+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 8 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the effects of enicepatide, a dual GLP-1GIP receptor agonist, for weight management in adults who have obesity or overweight with at least one related health condition, but do not have Type 2 diabetes. The study is a phase III, randomized, double-blind, placebo-controlled trial designed to assess the safety and efficacy of multiple doses of enicepatide compared with placebo. Participants will be randomly assigned to receive one of several dosing regimens of enicepatide or a placebo, administered once weekly using an integrated drug-device combination product. The treatment period lasts for 72 weeks, during which participants will self-administer the injections or receive assistance if needed. The placebo is volume-matched to the active drug to maintain blinding. Throughout the study, participants will have their body weight and other health measures evaluated regularly. Assessments include changes in waist circumference, blood glucose, insulin, cholesterol levels, blood pressure, and health-related quality of life. Safety is monitored by tracking adverse events and questionnaires related to mental health. The primary outcome is the percentage change in body weight from baseline to week 72, and the total participation duration covers this entire period.

Age: 18Years +All GendersPhase 3
209 locations
P

Actively Recruiting

Researchers are evaluating the drug efruxifermin EFX in adults with compensated cirrhosis caused by NASH Nonalcoholic Steatohepatitis or MASH Metabolic Dysfunction-Associated Steatohepatitis. This phase 3, randomized, double-blind, placebo-controlled study aims to assess the safety and efficacy of EFX in slowing disease progression and improving liver health over several years. Participants will be randomly assigned to receive either EFX 50 mg or a placebo, both given by subcutaneous injection. The study includes two cohorts one with biopsy-proven compensated cirrhosis and metabolic features, and another diagnosed either by biopsy or non-invasive methods. Treatment and follow-up will continue for up to five years to monitor outcomes. Throughout the study, participants will undergo regular assessments including liver fibrosis markers, liver injury markers, lipoproteins, insulin sensitivity, glycemic control, and body weight changes. Safety will be closely monitored through laboratory tests, ECGs, ultrasounds, and vital signs. The primary outcome measures include time to significant clinical events like disease progression or liver decompensation and improvements in fibrosis and steatohepatitis, with follow-up extending up to five years.

Age: 18Years - 80YearsAll GendersPhase 3
345 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of efruxifermin EFX in adults with non-cirrhotic nonalcoholic steatohepatitis NASH or metabolic dysfunction-associated steatohepatitis MASH who have moderate to advanced liver fibrosis stage 2 or 3. This Phase 3, multi-center study randomly assigns participants to different treatment groups and compares EFX with a placebo to see its impact on liver health and related clinical outcomes. Participants are divided into two groups one with about 750 subjects having confirmed NASHMASH and fibrosis stage 2 or 3, and another with about 900 subjects with fibrosis stage 3 regardless of their NAFLD activity score. They receive either 28 mg or 50 mg of EFX or a matching placebo through weekly injections under the skin. The study includes a screening period up to 12 weeks, a 52-week treatment phase for the first group, a 96-week phase for the second group, and an extended follow-up period lasting up to around 240 weeks, plus a follow-up visit about a month after the last dose. During the study, participants undergo liver biopsies, blood tests, imaging scans like FibroScan, and assessments of liver fibrosis markers and metabolism-related measures. Researchers monitor changes in liver tissue, liver function tests, cholesterol, blood sugar control, body weight, and safety indicators over time. Even if participants stop the study drug early, they may continue with scheduled assessments to support long-term evaluation of treatment effects and safety throughout the study duration.

Age: 18Years - 80YearsAll GendersPhase 3
359 locations
P

Actively Recruiting

Researchers are evaluating the safety, tolerability, and effects of HU6 in adults aged 30 years or older diagnosed with metabolic dysfunction-associated steatohepatitis MASH. The study aims to assess how HU6 affects liver fat content and other symptoms related to MASH, along with understanding its pharmacokinetics and safety profile. This is a phase 2a, randomized, double-blind, placebo-controlled trial sponsored by Rivus Pharmaceuticals, Inc. Participants are randomly assigned to one of four groups receiving either HU6 at 450 mg once daily, HU6 at 300 mg twice daily, placebo once daily, or placebo twice daily. The trial has two parts a blinded intervention period followed by an optional open-label extension for those who complete the first phase. The blinded period includes screening, treatment, an end of treatment or early termination visit, a safety follow-up visit, and two long-term follow-up visits. During the study, participants will undergo assessments including MRI scans to measure liver fat, laboratory tests, and monitoring of drug levels in the blood. Researchers will track adverse events and measure the drugs pharmacokinetics over 26 weeks. The total study duration includes multiple visits for safety and long-term observation to better understand the effects and safety of HU6 in treating MASH.

Age: 30Years +All GendersPhase 2
31 locations
E

Actively Recruiting

Researchers are evaluating a medicine called survodutide in adults aged 18 and older who have confirmed non-alcoholic steatohepatitis NASH or metabolic-associated steatohepatitis MASH with cirrhosis, and a body mass index BMI of 27 kgm2 or higher, or 25 kgm2 for Asian participants. The study aims to find out if survodutide helps improve liver function and related health outcomes in these individuals. People with other chronic liver diseases or high alcohol intake are not eligible to participate. Participants are randomly assigned to one of two groups one group receives once-weekly injections of survodutide, and the other group receives a placebo injection that looks the same but contains no medicine. Both groups receive counseling to encourage dietary changes and regular exercise. The study is double-blinded, meaning neither participants nor doctors know which treatment is given. The trial lasts up to 4 and a half years, with visits either in person or via video calls scheduled every 2, 4, or 6 weeks for about 17 months, then every 3 months afterwards. Throughout the study, researchers monitor participants health, body weight, and any side effects. They use imaging methods to measure liver parameters and collect symptom questionnaires. The main outcome measured is the time until serious liver-related events occur, such as liver transplant or worsening liver function. Secondary outcomes include changes in liver fibrosis, body weight, blood sugar control, liver stiffness, and other health markers. This thorough monitoring helps compare the effects of survodutide to placebo over the long term.

Age: 18Years +All GendersPhase 3
447 locations
E

Actively Recruiting

Researchers are studying adults aged 18 and older who live with obesity and have a liver disease known as non-alcoholic steatohepatitis NASH or metabolic associated steatohepatitis MASH with moderate or advanced liver fibrosis. The study aims to evaluate whether a medicine called survodutide can improve liver function in people with these conditions. It is a Phase III, randomized, double-blind, placebo-controlled trial conducted at multiple centers. Participants are randomly assigned to one of two groups one receives weekly injections of survodutide, and the other receives placebo injections that look the same but contain no medicine. The survodutide dose is gradually increased until reaching the target dose. All participants receive counseling on diet and exercise. The study includes two parts the first focuses on the effect of survodutide on NASH and fibrosis over one year, and the second assesses its long-term safety and effectiveness over up to seven years. Participants stay in the study for up to seven years, attending regular visits either in person or remotely via video call. Visits occur every two weeks initially, then every four to six weeks, and later every three months. Doctors monitor health, record any side effects, and measure body weight and digestive symptoms. Liver assessments include imaging and biopsies at selected visits. Participants also complete questionnaires about symptoms and quality of life. Researchers compare results between the groups to assess the medicines effects on liver health and related outcomes.

Age: 18Years +All GendersPhase 3
532 locations
L

Actively Recruiting

This research aims to evaluate the long-term safety of rimegepant in treating acute migraine attacks in children and adolescents aged 6 to under 18 years. The study focuses on monitoring how well participants tolerate the medication over time and tracking any side effects or safety concerns during treatment. Participants will receive oral doses of rimegepant at 75 mg, 50 mg, or 35 mg as orally disintegrating tablets ODT for acute migraine treatment. This open-label, single-group study follows participants for approximately 58 weeks to assess safety and tolerability, including monitoring liver-related adverse events. Throughout the study, participants will undergo regular assessments including blood sampling and clinical evaluations to monitor adverse events and overall health. Researchers will record the frequency and severity of side effects, serious adverse events, and any lab abnormalities. The total participation duration extends up to 58 weeks, with ongoing safety monitoring during this period.

Age: 6Years - 17YearsAll GendersPhase 3
124 locations
E

Actively Recruiting

Researchers are evaluating the safety, tolerability, and pharmacodynamic effects of AZD2389 in adults with steatotic liver disease SLD and advanced fibrosis. This phase IIa study aims to better understand how this oral drug works in treating chronic liver diseases with advanced fibrosis, including cirrhosis. The research involves about 230 screened participants, with 104 adults expected to be randomly assigned to treatment groups. Participants will be divided into two groups one receiving AZD2389 orally for up to 24 weeks and the other receiving a placebo. The study lasts approximately 32 weeks, including 4 weeks of screening, 24 weeks of treatment, and a 4-week follow-up. Visits occur about every 4 weeks except between visits 2 and 4, which happen every 2 weeks. The study is double-blind and randomized to compare the effects of AZD2389 versus placebo. During the trial, participants will have regular assessments including blood pressure, heart rate, oxygen levels, body temperature, respiratory rate, and laboratory tests of blood and urine samples. The main outcome measured is the change in Enhanced Liver Fibrosis ELF score after 24 weeks. Additional tests include liver stiffness and collagen markers. Safety will be monitored throughout treatment and follow-up. Participants involvement will last up to 32 weeks, with multiple visits to track health and liver function.

Age: 18Years +All GendersPhase 2
22 locations